AKT1 and breast carcinoma: TAM exerts its function as a GPR30 agonist that activates the epidermal growth factor receptor (EGFR) intracellular signaling, MAPK and PI3K/AKT signaling pathways, leading to TAM resistance in breast cancer [179,180,181,182].